1.         Thamri, A.; Letourneau, M.; Djoboulian, A.; Chatenet, D.; Deziel, E.; Castonguay, A.; Perreault, J. Peptide modification results in the formation of a dimer with a 60-fold enhanced antimicrobial activity. PLoS One 2017, 12, e0173783.

2.         Tadevosyan, A.; Xiao, J.; Surinkaew, S.; Naud, P.; Merlen, C.; Harada, M.; Qi, X.; Chatenet, D.; Fournier, A.; Allen, B. G.; Nattel, S. Intracellular Angiotensin-II Interacts With Nuclear Angiotensin Receptors in Cardiac Fibroblasts and Regulates RNA Synthesis, Cell Proliferation, and Collagen Secretion. J Am Heart Assoc 2017, 6.

3.         Strack, M.; Billard, E.; Chatenet, D.; Lubell, W. D. Urotensin core mimics that modulate the biological activity of urotensin-II related peptide but not urotensin-II. Bioorg Med Chem Lett 2017, 27, 3412-3416.

4.         Chatenet, D.; Hebert, T. E. Understanding GPCR signaling in the brain- the path to CNS drug discovery. Curr Opin Pharmacol 2017, 32, v-vii.

5.         Billard, E.; Letourneau, M.; Hebert, T. E.; Chatenet, D. Insight into the role of urotensin II-related peptide tyrosine residue in UT activation. Biochem Pharmacol 2017, 144, 100-107.

6.         Tadevosyan, A.; Villeneuve, L. R.; Fournier, A.; Chatenet, D.; Nattel, S.; Allen, B. G. Caged ligands to study the role of intracellular GPCRs. Methods 2016, 92, 72-7.

7.         Merlino, F.; Yousif, A. M.; Billard, E.; Dufour-Gallant, J.; Turcotte, S.; Grieco, P.; Chatenet, D.; Lubell, W. D. Urotensin II((4-11)) Azasulfuryl Peptides: Synthesis and Biological Activity. J Med Chem 2016, 59, 4740-52.

8.         Lamine-Ajili, A.; Fahmy, A. M.; Letourneau, M.; Chatenet, D.; Labonte, P.; Vaudry, D.; Fournier, A. Effect of the pituitary adenylate cyclase-activating polypeptide on the autophagic activation observed in in vitro and in vivo models of Parkinson's disease. Biochim Biophys Acta 2016, 1862, 688-695.

9.         Lamine, A.; Letourneau, M.; Doan, N. D.; Maucotel, J.; Couvineau, A.; Vaudry, H.; Chatenet, D.; Vaudry, D.; Fournier, A. Characterizations of a synthetic pituitary adenylate cyclase-activating polypeptide analog displaying potent neuroprotective activity and reduced in vivo cardiovascular side effects in a Parkinson's disease model. Neuropharmacology 2016, 108, 440-50.

10.       Vladoiu, M. C.; Labrie, M.; Letourneau, M.; Egesborg, P.; Gagne, D.; Billard, E.; Grosset, A. A.; Doucet, N.; Chatenet, D.; St-Pierre, Y. Design of a peptidic inhibitor that targets the dimer interface of a prototypic galectin. Oncotarget 2015, 6, 40970-80.

11.       Vaudry, H.; Leprince, J.; Chatenet, D.; Fournier, A.; Lambert, D. G.; Le Mevel, J. C.; Ohlstein, E. H.; Schwertani, A.; Tostivint, H.; Vaudry, D. International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, urotensin II-related peptide, and their receptor: from structure to function. Pharmacol Rev 2015, 67, 214-58.

12.       Tadevosyan, A.; Letourneau, M.; Folch, B.; Doucet, N.; Villeneuve, L. R.; Mamarbachi, A. M.; Petrin, D.; Hebert, T. E.; Fournier, A.; Chatenet, D.; Allen, B. G.; Nattel, S. Photoreleasable ligands to study intracrine angiotensin II signalling. J Physiol 2015, 593, 521-39.

13.       Dufour-Gallant, J.; Chatenet, D.; Lubell, W. D. De Novo Conception of Small Molecule Modulators Based on Endogenous Peptide Ligands: Pyrrolodiazepin-2-one gamma-Turn Mimics That Differentially Modulate Urotensin II Receptor-Mediated Vasoconstriction ex Vivo. J Med Chem 2015, 58, 4624-37.

14.       Doan, N. D.; Poujol de Molliens, M.; Letourneau, M.; Fournier, A.; Chatenet, D. Optimization of on-resin palladium-catalyzed Sonogashira cross-coupling reaction for peptides and its use in a structure-activity relationship study of a class B GPCR ligand. Eur J Med Chem 2015, 104, 106-14.

15.       Chatenet, D.; Bourgault, S.; Fournier, A. Design and application of light-activated probes for cellular signaling. Methods Mol Biol 2015, 1234, 17-30.

16.       Tchoumi Neree, A.; Nguyen, P. T.; Chatenet, D.; Fournier, A.; Bourgault, S. Secondary conformational conversion is involved in glycosaminoglycans-mediated cellular uptake of the cationic cell-penetrating peptide PACAP. FEBS Lett 2014, 588, 4590-6.

17.       Nguyen, T. T.; Folch, B.; Letourneau, M.; Truong, N. H.; Doucet, N.; Fournier, A.; Chatenet, D. Design of a truncated cardiotoxin-I analogue with potent insulinotropic activity. J Med Chem 2014, 57, 2623-33.

18.       Vaniotis, G.; Glazkova, I.; Merlen, C.; Smith, C.; Villeneuve, L. R.; Chatenet, D.; Therien, M.; Fournier, A.; Tadevosyan, A.; Trieu, P.; Nattel, S.; Hebert, T. E.; Allen, B. G. Regulation of cardiac nitric oxide signaling by nuclear beta-adrenergic and endothelin receptors. J Mol Cell Cardiol 2013, 62, 58-68.

19.       Merlen, C.; Farhat, N.; Luo, X.; Chatenet, D.; Tadevosyan, A.; Villeneuve, L. R.; Gillis, M. A.; Nattel, S.; Thorin, E.; Fournier, A.; Allen, B. G. Intracrine endothelin signaling evokes IP3-dependent increases in nucleoplasmic Ca(2)(+) in adult cardiac myocytes. J Mol Cell Cardiol 2013, 62, 189-202.

20.       Chatenet, D.; Letourneau, M.; Nguyen, Q. T.; Doan, N. D.; Dupuis, J.; Fournier, A. Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation. Br J Pharmacol 2013, 168, 807-21.

21.       Chatenet, D.; Folch, B.; Feytens, D.; Letourneau, M.; Tourwe, D.; Doucet, N.; Fournier, A. Development and pharmacological characterization of conformationally constrained urotensin II-related peptide agonists. J Med Chem 2013, 56, 9612-22.

22.       Nguyen, T. T.; Letourneau, M.; Chatenet, D.; Fournier, A. Presence of urotensin-II receptors at the cell nucleus: specific tissue distribution and hypoxia-induced modulation. Int J Biochem Cell Biol 2012, 44, 639-47.

23.       Nguyen, T. T.; Folch, B.; Letourneau, M.; Vaudry, D.; Truong, N. H.; Doucet, N.; Chatenet, D.; Fournier, A. Cardiotoxin-I: an unexpectedly potent insulinotropic agent. Chembiochem 2012, 13, 1805-12.

24.       Doan, N. D.; Nguyen, T. T.; Letourneau, M.; Turcotte, K.; Fournier, A.; Chatenet, D. Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart. Br J Pharmacol 2012, 166, 243-57.

25.       Doan, N. D.; Letourneau, M.; Vaudry, D.; Doucet, N.; Folch, B.; Vaudry, H.; Fournier, A.; Chatenet, D. Design and characterization of novel cell-penetrating peptides from pituitary adenylate cyclase-activating polypeptide. J Control Release 2012, 163, 256-65.

26.       Doan, N. D.; Chatenet, D.; Letourneau, M.; Vaudry, H.; Vaudry, D.; Fournier, A. Receptor-independent cellular uptake of pituitary adenylate cyclase-activating polypeptide. Biochim Biophys Acta 2012, 1823, 940-9.

27.       Chatenet, D.; Nguyen, T. T.; Letourneau, M.; Fournier, A. Update on the urotensinergic system: new trends in receptor localization, activation, and drug design. Front Endocrinol (Lausanne) 2012, 3, 174.

28.       Chatenet, D.; Nguyen, Q. T.; Letourneau, M.; Dupuis, J.; Fournier, A. Urocontrin, a novel UT receptor ligand with a unique pharmacological profile. Biochem Pharmacol 2012, 83, 608-15.

29.       Fu, Y.; Letourneau, M.; Chatenet, D.; Dupuis, J.; Fournier, A. Characterization of iodinated adrenomedullin derivatives suitable for lung nuclear medicine. Nucl Med Biol 2011, 38, 867-74.

30.       Doan, N. D.; Bourgault, S.; Dejda, A.; Letourneau, M.; Detheux, M.; Vaudry, D.; Vaudry, H.; Chatenet, D.; Fournier, A. Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects. Biochem Pharmacol 2011, 81, 552-61.

31.       Chatenet, D.; Cescato, R.; Waser, B.; Erchegyi, J.; Rivier, J. E.; Reubi, J. C. Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers. EJNMMI Res 2011, 1, 21.

32.       Bourgault, S.; Chatenet, D.; Wurtz, O.; Doan, N. D.; Leprince, J.; Vaudry, H.; Fournier, A.; Vaudry, D. Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug. Curr Pharm Des 2011, 17, 1002-24.

33.       Vaudry, H.; Do Rego, J. C.; Le Mevel, J. C.; Chatenet, D.; Tostivint, H.; Fournier, A.; Tonon, M. C.; Pelletier, G.; Conlon, J. M.; Leprince, J. Urotensin II, from fish to human. Ann N Y Acad Sci 2010, 1200, 53-66.

34.       Jarry, M.; Diallo, M.; Lecointre, C.; Desrues, L.; Tokay, T.; Chatenet, D.; Leprince, J.; Rossi, O.; Vaudry, H.; Tonon, M. C.; Prezeau, L.; Castel, H.; Gandolfo, P. The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation. Biochem J 2010, 428, 113-24.

35.       Fu, Y.; Letourneau, M.; Nguyen, Q. T.; Chatenet, D.; Dupuis, J.; Fournier, A. Characterization of the adrenomedullin receptor acting as the target of a new radiopharmaceutical biomolecule for lung imaging. Eur J Pharmacol 2009, 617, 118-23.

36.       Leprince, J.; Chatenet, D.; Dubessy, C.; Fournier, A.; Pfeiffer, B.; Scalbert, E.; Renard, P.; Pacaud, P.; Oulyadi, H.; Segalas-Milazzo, I.; Guilhaudis, L.; Davoust, D.; Tonon, M. C.; Vaudry, H. Structure-activity relationships of urotensin II and URP. Peptides 2008, 29, 658-73.

37.       Dubessy, C.; Cartier, D.; Lectez, B.; Bucharles, C.; Chartrel, N.; Montero-Hadjadje, M.; Bizet, P.; Chatenet, D.; Tostivint, H.; Scalbert, E.; Leprince, J.; Vaudry, H.; Jegou, S.; Lihrmann, I. Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction. J Neurochem 2008, 107, 361-74.

38.       Diallo, M.; Jarry, M.; Desrues, L.; Castel, H.; Chatenet, D.; Leprince, J.; Vaudry, H.; Tonon, M. C.; Gandolfo, P. [Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes. Peptides 2008, 29, 813-9.

39.       Desrues, L.; Lefebvre, T.; Diallo, M.; Gandolfo, P.; Leprince, J.; Chatenet, D.; Vaudry, H.; Tonon, M. C.; Castel, H. Effect of GABA A receptor activation on UT-coupled signaling pathways in rat cortical astrocytes. Peptides 2008, 29, 727-34.

40.       Chuquet, J.; Lecrux, C.; Chatenet, D.; Leprince, J.; Chazalviel, L.; Roussel, S.; MacKenzie, E. T.; Vaudry, H.; Touzani, O. Effects of urotensin-II on cerebral blood flow and ischemia in anesthetized rats. Exp Neurol 2008, 210, 577-84.

41.       Bruzzone, F.; Lectez, B.; Alexandre, D.; Jegou, S.; Mounien, L.; Tollemer, H.; Chatenet, D.; Leprince, J.; Vallarino, M.; Vaudry, H.; Chartrel, N. Distribution of 26RFa binding sites and GPR103 mRNA in the central nervous system of the rat. J Comp Neurol 2007, 503, 573-91.

42.       Leprince, J.; Cosquer, D.; Bellemere, G.; Chatenet, D.; Tollemer, H.; Jegou, S.; Tonon, M. C.; Vaudry, H. Catabolism of the octadecaneuropeptide ODN by prolyl endopeptidase: identification of an unusual cleavage site. Peptides 2006, 27, 1561-9.

43.       Jegou, S.; Cartier, D.; Dubessy, C.; Gonzalez, B. J.; Chatenet, D.; Tostivint, H.; Scalbert, E.; LePrince, J.; Vaudry, H.; Lihrmann, I. Localization of the urotensin II receptor in the rat central nervous system. J Comp Neurol 2006, 495, 21-36.

44.       Chatenet, D.; Dubessy, C.; Boularan, C.; Scalbert, E.; Pfeiffer, B.; Renard, P.; Lihrmann, I.; Pacaud, P.; Tonon, M. C.; Vaudry, H.; Leprince, J. Structure-activity relationships of a novel series of urotensin II analogues: identification of a urotensin II antagonist. J Med Chem 2006, 49, 7234-8.

45.       Castel, H.; Diallo, M.; Chatenet, D.; Leprince, J.; Desrues, L.; Schouft, M. T.; Fontaine, M.; Dubessy, C.; Lihrmann, I.; Scalbert, E.; Malagon, M.; Vaudry, H.; Tonon, M. C.; Gandolfo, P. Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes. J Neurochem 2006, 99, 582-95.

46.       Bruzzone, F.; Lectez, B.; Tollemer, H.; Leprince, J.; Dujardin, C.; Rachidi, W.; Chatenet, D.; Baroncini, M.; Beauvillain, J. C.; Vallarino, M.; Vaudry, H.; Chartrel, N. Anatomical distribution and biochemical characterization of the novel RFamide peptide 26RFa in the human hypothalamus and spinal cord. J Neurochem 2006, 99, 616-27.

47.       Do-Rego, J. C.; Chatenet, D.; Orta, M. H.; Naudin, B.; Le Cudennec, C.; Leprince, J.; Scalbert, E.; Vaudry, H.; Costentin, J. Behavioral effects of urotensin-II centrally administered in mice. Psychopharmacology (Berl) 2005, 183, 103-17.

48.       Silvestre, R. A.; Egido, E. M.; Hernandez, R.; Leprince, J.; Chatenet, D.; Tollemer, H.; Chartrel, N.; Vaudry, H.; Marco, J. Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur J Endocrinol 2004, 151, 803-9.

49.       Chatenet, D.; Dubessy, C.; Leprince, J.; Boularan, C.; Carlier, L.; Segalas-Milazzo, I.; Guilhaudis, L.; Oulyadi, H.; Davoust, D.; Scalbert, E.; Pfeiffer, B.; Renard, P.; Tonon, M. C.; Lihrmann, I.; Pacaud, P.; Vaudry, H. Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 2004, 25, 1819-30.

50.       Chartrel, N.; Leprince, J.; Dujardin, C.; Chatenet, D.; Tollemer, H.; Baroncini, M.; Balment, R. J.; Beauvillain, J. C.; Vaudry, H. Biochemical characterization and immunohistochemical localization of urotensin II in the human brainstem and spinal cord. J Neurochem 2004, 91, 110-8.

51.       Labarrere, P.; Chatenet, D.; Leprince, J.; Marionneau, C.; Loirand, G.; Tonon, M. C.; Dubessy, C.; Scalbert, E.; Pfeiffer, B.; Renard, P.; Calas, B.; Pacaud, P.; Vaudry, H. Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. J Enzyme Inhib Med Chem 2003, 18, 77-88.

52.       Grison, C.; Comoy, C.; Chatenet, D.; Coutrot, P. Synthesis of P-chiral enephosphonic acid derivatives. J Organomet. Chem. 2002, 662, 83-97.



David Chatenet

Institut national de la recherche scientifique
Centre Armand-Frappier Santé Biotechnologie
Université du Québec
Réseau International des Instituts Pasteur
531, Boulevard des Prairies
Laval (Quebec) H7V 1B7 CANADA
Tél.: (450) 687-5010
Cell.: (514) 618-0609